Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer

被引：0
|
作者：
Kraeber-Bodere, F. [1 ,2 ]
Goldenberg, D. M. [3 ]
Chatal, J. F. [4 ]
Barbet, J. [2 ,4 ]
机构：
[1] Univ Hosp, Dept Nucl Med, Nantes, France
[2] Univ Nantes, INSERM, Canc Res Ctr, Nantes, France
[3] Ctr Mol Med & Immunol, Garden State Canc Ctr, Belleville, NJ USA
[4] Univ Nantes, Arronax Cyclotron, Nantes, France
来源：
CURRENT ONCOLOGY | 2009年 / 16卷 / 05期
关键词：
Pretargeted radioimmunotherapy; medullary thyroid cancer; calcitonin; BISPECIFIC ANTIBODY; PROGNOSTIC-FACTORS; BIVALENT HAPTEN; IMATINIB MESYLATE; FOLLOW-UP; CARCINOMA; SURVIVAL; CHEMOEMBOLIZATION; OPTIMIZATION; CALCITONIN;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：296 / 301
页数：6
相关论文
共 50 条
  • [41] Medical Management of Metastatic Medullary Thyroid Cancer
    Maxwell, Jessica E.
    Sherman, Scott K.
    O'Dorisio, Thomas M.
    Howe, James R.
    CANCER, 2014, 120 (21) : 3287 - 3301
  • [42] Medullary thyroid carcinoma: The third most common thyroid cancer reviewed
    Stamatakos, Michael
    Paraskeva, Panoraia
    Stefanaki, Charikleia
    Katsaronis, Paraskevas
    Lazaris, Andreas
    Safioleas, Konstantinos
    Kontzoglou, Konstantinos
    ONCOLOGY LETTERS, 2011, 2 (01) : 49 - 53
  • [43] Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma
    Membreno, Rosemery
    Cook, Brendon E.
    Fung, Kimberly
    Lewis, Jason S.
    Zeglis, Brian M.
    MOLECULAR PHARMACEUTICS, 2018, 15 (04) : 1729 - 1734
  • [44] Medullary Thyroid Cancer Overview and case study of a rare cancer
    Jakobs, Lynn
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2018, 22 (02) : E37 - E43
  • [45] Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
    Nagilla, Madhavi
    Brown, Rebecca L.
    Cohen, Ezra E. W.
    ADVANCES IN THERAPY, 2012, 29 (11) : 925 - 934
  • [46] Value of lymph node ratio as a prognostic factor of recurrence in medullary thyroid cancer
    Hao, Weijing
    Zhao, Jingzhu
    Guo, Fengli
    Gu, Pengfei
    Zhang, Jinming
    Huang, Dongmei
    Ruan, Xianhui
    Zeng, Yu
    Zheng, Xiangqian
    Gao, Ming
    PEERJ, 2023, 11
  • [47] Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft
    Kraeber-Bodéré, F
    Faivre-Chauvet, A
    Saï-Maurel, C
    Gautherot, E
    Fiche, M
    Campion, L
    Le Boterff, J
    Barbet, J
    Chatal, JF
    Thédrez, P
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (01) : 198 - 204
  • [48] Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis
    de Castroneves, Luciana Audi
    Negrao, Marcelo Vailati
    Costa de Freitas, Ricardo Miguel
    Papadia, Carla
    Lima, Jose Viana, Jr.
    Fukushima, Julia T.
    Simao, Eduardo Furquim
    Vamondes Kulcsar, Marco Aurelio
    Tavares, Marcos Roberto
    de Lima Jorge, Alexander Augusto
    de Castro, Gilberto
    Hoff, Paulo Marcelo
    Hoff, Ana Oliveira
    THYROID, 2016, 26 (03) : 414 - 419
  • [49] Calcitonin determination for early diagnosis of medullary thyroid cancer
    Karges, W.
    CHIRURG, 2010, 81 (07): : 620 - +
  • [50] Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
    Werner, R. A.
    Schmid, J. S.
    Muegge, D. O.
    Lueckerath, K.
    Higuchi, T.
    Haenscheid, H.
    Grelle, I.
    Reiners, C.
    Herrmann, K.
    Buck, A. K.
    Lapa, C.
    MEDICINE, 2015, 94 (45) : e2016
12345